Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
World J Urol
; 41(12): 3413-3420, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37698632
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ureteral Neoplasms
/
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Kidney Neoplasms
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
World J Urol
Year:
2023
Document type:
Article
Affiliation country:
Francia
Country of publication:
Alemania